scispace - formally typeset
C

Claire Advokat

Researcher at Louisiana State University

Publications -  46
Citations -  1525

Claire Advokat is an academic researcher from Louisiana State University. The author has contributed to research in topics: Nociception & Morphine. The author has an hindex of 21, co-authored 46 publications receiving 1455 citations.

Papers
More filters
Journal ArticleDOI

What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).

TL;DR: The relevant literature concerning cognitive effects of amphetamine and methylphenidate, was reviewed, with an emphasis on research conducted in adults diagnosed with attention-deficit/hyperactivity disorder, and evidence does not support the conclusion that stimulants are cognitive 'enhancers.
Journal ArticleDOI

College students with and without ADHD: comparison of self-report of medication usage, study habits, and academic achievement.

TL;DR: Preliminary data suggested that good study habits alone, even without stimulants, could overcome the achievement disparity of ADHD students, but stimulant medications alone did not eliminate the academic achievement deficit of ADHD undergraduates.
Journal ArticleDOI

Licit and Illicit Use of Medications for Attention-Deficit Hyperactivity Disorder in Undergraduate College Students

TL;DR: Drug use was associated with a lower GPA in ADHD-diagnosed students than in students without ADHD and the ADHD group and the No ADHD, Illicit Use group reported significantly greater use of all other drugs than did the NoADHD, No Illicit use group.
Journal ArticleDOI

Continuous Performance Test (CPT) of college students with ADHD, psychiatric disorders, cognitive deficits, or no diagnosis.

TL;DR: The Conner’s Continuous Performance Test reliably differentiated between individuals with ADHD and both normal college students and individuals with psychiatric diagnoses but not persons with learning/cognitive disorders.
Journal ArticleDOI

Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation.

TL;DR: This work compared the side effect profiles of both the typical and atypical antipsychotics using a comprehensive instrument, the Matson Evaluation of Drug Side Effects (MEDS) scale, and found both groups showed significantly fewer overall side effects than participants taking typical antipsychotic medications.